RNAC vs. BMY
Compare and contrast key facts about Cartesian Therapeutics Inc. (RNAC) and Bristol-Myers Squibb Company (BMY).
Performance
RNAC vs. BMY - Performance Comparison
Loading graphics...
RNAC vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RNAC Cartesian Therapeutics Inc. | -11.37% | -59.74% | -13.40% | -38.99% | -65.34% | 7.59% | 27.31% | -10.53% | -72.88% | -42.80% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
RNAC:
$165.97M
BMY:
$125.99B
RNAC:
-$4.98
BMY:
$3.46
RNAC:
59.72
BMY:
2.61
RNAC:
$2.80M
BMY:
$48.19B
RNAC:
-$10.95M
BMY:
$30.43B
RNAC:
-$17.74M
BMY:
$13.82B
Returns By Period
In the year-to-date period, RNAC achieves a -11.37% return, which is significantly lower than BMY's 15.79% return.
RNAC
- 1D
- 3.90%
- 1M
- -15.92%
- YTD
- -11.37%
- 6M
- -37.60%
- 1Y
- -48.84%
- 3Y*
- -46.49%
- 5Y*
- -45.74%
- 10Y*
- —
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RNAC vs. BMY — Risk / Return Rank
RNAC
BMY
RNAC vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cartesian Therapeutics Inc. (RNAC) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RNAC | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.55 | 0.31 | -0.86 |
Sortino ratioReturn per unit of downside risk | -0.51 | 0.64 | -1.15 |
Omega ratioGain probability vs. loss probability | 0.94 | 1.08 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | -0.90 | 0.25 | -1.14 |
Martin ratioReturn relative to average drawdown | -1.47 | 0.39 | -1.86 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| RNAC | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.55 | 0.31 | -0.86 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.52 | 0.15 | -0.67 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.39 | 0.35 | -0.74 |
Correlation
The correlation between RNAC and BMY is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
RNAC vs. BMY - Dividend Comparison
RNAC has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RNAC Cartesian Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
RNAC vs. BMY - Drawdown Comparison
The maximum RNAC drawdown since its inception was -99.26%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for RNAC and BMY.
Loading graphics...
Drawdown Indicators
| RNAC | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.26% | -72.03% | -27.23% |
Max Drawdown (1Y)Largest decline over 1 year | -57.52% | -25.79% | -31.73% |
Max Drawdown (5Y)Largest decline over 5 years | -96.11% | -47.67% | -48.44% |
Max Drawdown (10Y)Largest decline over 10 years | — | -47.67% | — |
Current DrawdownCurrent decline from peak | -99.19% | -12.07% | -87.12% |
Average DrawdownAverage peak-to-trough decline | -80.13% | -22.40% | -57.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.11% | 16.06% | +19.05% |
Volatility
RNAC vs. BMY - Volatility Comparison
Cartesian Therapeutics Inc. (RNAC) has a higher volatility of 36.78% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that RNAC's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| RNAC | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 36.78% | 6.68% | +30.10% |
Volatility (6M)Calculated over the trailing 6-month period | 58.28% | 19.39% | +38.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 89.63% | 28.61% | +61.02% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 88.17% | 23.68% | +64.49% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 90.47% | 25.08% | +65.39% |
Financials
RNAC vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Cartesian Therapeutics Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities